摘要: Abstract B cells play a central role in the pathogenesis of systemic lupus erythematosus (SLE), including unique capacity plasma as ultimately differentiated autoreactive to produce autoantibodies. These antibodies reacting against self-antigens participate induction and maintenance tissue damage represent hallmarks SLE, which is characterized by largest variety specificities, with 180 autoantibodies so far described. The SLE further highlighted fact that only successful new therapy for more than 50 years an agent blocks BAFF/BLyS (B-cell activating factor or lymphocyte stimulator)—belimumab interferes cell survival.